person · Reporting owner
Scharen-Guivel Hilda Frederique
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IRADIMED CORPIRMD · Entity 4896 | Director | June 04, 2026 | June 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IRADIMED CORP
Report date June 04, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,598 |
Last balance in matching sequence
After 2026-06-04 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-06-04 · Sale · Disposed 1,766 · Balance 6,832 F1: This transaction was executed at $95.00. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: The shares reported as beneficially owned following the reported transaction consist of shares acquired upon the vesting and settlement of restricted stock units granted in connection with the reporting person's service as a director. Such shares were acquired in multiple vesting transactions occurring on various dates. Row 2 · 2026-06-04 · Sale · Disposed 1,234 · Balance 5,598 F1: This transaction was executed at $95.00. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: The shares reported as beneficially owned following the reported transaction consist of shares acquired upon the vesting and settlement of restricted stock units granted in connection with the reporting person's service as a director. Such shares were acquired in multiple vesting transactions occurring on various dates. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed at $95.00. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: The shares reported as beneficially owned following the reported transaction consist of shares acquired upon the vesting and settlement of restricted stock units granted in connection with the reporting person's service as a director. Such shares were acquired in multiple vesting transactions occurring on various dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 4, 2026 20:21 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 1,234 | $95.00 | $117,230.00 |
DisclosureSEC source: 0001950129-26-000006 · wk-form4_1780604510.xml · nonDerivative · entry 2 Scharen-Guivel Hilda Frederique · CIK 0001950129 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,598 F1 · price: This transaction was executed at $95.00. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: The shares reported as beneficially owned following the reported transaction consist of shares acquired upon the vesting and settlement of restricted stock units granted in connection with the reporting person's service as a director. Such shares were acquired in multiple vesting transactions occurring on various dates. Read SEC document |
| June 04, 2026 Filed Jun 4, 2026 20:21 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 1,766 | $95.00 | $167,770.00 |
DisclosureSEC source: 0001950129-26-000006 · wk-form4_1780604510.xml · nonDerivative · entry 1 Scharen-Guivel Hilda Frederique · CIK 0001950129 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,832 F1 · price: This transaction was executed at $95.00. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: The shares reported as beneficially owned following the reported transaction consist of shares acquired upon the vesting and settlement of restricted stock units granted in connection with the reporting person's service as a director. Such shares were acquired in multiple vesting transactions occurring on various dates. Read SEC document |
| December 11, 2025 Filed Dec 12, 2025 22:00 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionRestricted Stock Units · Derivative | 905 | $0.00 | $0.00 |
DisclosureSEC source: 0001950129-25-000007 · form4-12122025_051215.xml · derivative · entry 2 Scharen-Guivel Hilda Frederique · CIK 0001950129 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 906 Underlying: Common Stock · 905 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On December 11, 2024, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: On December 11, 2024, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 11, 2025 Filed Dec 12, 2025 22:00 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionCommon Stock | 905 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001950129-25-000007 · form4-12122025_051215.xml · nonDerivative · entry 1 Scharen-Guivel Hilda Frederique · CIK 0001950129 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 22:30 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantRestricted Stock Units · Derivative | 1,026 | $0.00 | $0.00 |
DisclosureSEC source: 0001950129-25-000009 · form4-12152025_051205.xml · derivative · entry 1 Scharen-Guivel Hilda Frederique · CIK 0001950129 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,932 Underlying: Common Stock · 1,026 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On December 11, 2025, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 11, 2026. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: On December 11, 2025, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 11, 2026. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2025 Filed Dec 9, 2025 22:00 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionRestricted Stock Units · Derivative | 1,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001950129-25-000005 · form4-12092025_051206.xml · derivative · entry 2 Scharen-Guivel Hilda Frederique · CIK 0001950129 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,197 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On December 7, 2023, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2024. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: On December 7, 2023, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2024. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2025 Filed Dec 9, 2025 22:00 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionCommon Stock | 1,197 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001950129-25-000005 · form4-12092025_051206.xml · nonDerivative · entry 1 Scharen-Guivel Hilda Frederique · CIK 0001950129 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| October 14, 2025 Filed Oct 15, 2025 20:05 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionRestricted Stock Units · Derivative | 1,767 | $0.00 | $0.00 |
DisclosureSEC source: 0001950129-25-000003 · form4-10152025_041001.xml · derivative · entry 2 Scharen-Guivel Hilda Frederique · CIK 0001950129 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,767 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On October 14, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in three equal annual installments beginning on October 14, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: On October 14, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in three equal annual installments beginning on October 14, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| October 14, 2025 Filed Oct 15, 2025 20:05 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionCommon Stock | 1,767 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001950129-25-000003 · form4-10152025_041001.xml · nonDerivative · entry 1 Scharen-Guivel Hilda Frederique · CIK 0001950129 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 21:00 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantRestricted Stock Units · Derivative | 1,811 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029271 · form4-12132024_041207.xml · derivative · entry 1 Scharen-Guivel Hilda Frederique · CIK 0001950129 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,008 Underlying: Common Stock · 1,811 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On December 11, 2024, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: On December 11, 2024, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2024 Filed Dec 11, 2024 02:00 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionRestricted Stock Units · Derivative | 1,196 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-028902 · form4-12102024_091207.xml · derivative · entry 2 Scharen-Guivel Hilda Frederique · CIK 0001950129 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,197 Underlying: Common Stock · 1,196 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On December 7, 2023, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2024. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: On December 7, 2023, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2024. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2024 Filed Dec 11, 2024 02:00 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionCommon Stock | 1,196 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-028902 · form4-12102024_091207.xml · nonDerivative · entry 1 Scharen-Guivel Hilda Frederique · CIK 0001950129 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,729 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| October 14, 2024 Filed Oct 15, 2024 21:45 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionRestricted Stock Units · Derivative | 1,767 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-025137 · form4-10152024_051001.xml · derivative · entry 2 Scharen-Guivel Hilda Frederique · CIK 0001950129 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,767 Underlying: Common Stock · 1,767 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.expiration_date: On October 14, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in three equal annual installments beginning on October 14, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| October 14, 2024 Filed Oct 15, 2024 21:45 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionCommon Stock | 1,767 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-025137 · form4-10152024_051001.xml · nonDerivative · entry 1 Scharen-Guivel Hilda Frederique · CIK 0001950129 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,533 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 07, 2023 Filed Dec 11, 2023 23:00 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantRestricted Stock Units · Derivative | 2,393 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-016252 · form4-12112023_061210.xml · derivative · entry 1 Scharen-Guivel Hilda Frederique · CIK 0001950129 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,393 Underlying: Common Stock · 2,393 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On December 7, 2023, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2024. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: On December 7, 2023, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2024. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| October 23, 2023 Filed Oct 23, 2023 20:15 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionRestricted Stock Units · Derivative | 1,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-014482 · form4-10232023_041001.xml · derivative · entry 2 Scharen-Guivel Hilda Frederique · CIK 0001950129 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,534 Underlying: Common Stock · 1,766 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.expiration_date: On October 14, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in three equal annual installments beginning on October 14, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| October 23, 2023 Filed Oct 23, 2023 20:15 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionCommon Stock | 1,766 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-014482 · form4-10232023_041001.xml · nonDerivative · entry 1 Scharen-Guivel Hilda Frederique · CIK 0001950129 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,766 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| October 14, 2022 Filed Oct 18, 2022 22:52 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantRestricted Stock Units · Derivative | 5,300 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-22-000621 · form4.xml · derivative · entry 1 Scharen-Guivel Hilda Frederique · CIK 0001950129 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,300 Underlying: Common Stock · 5,300 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock. F2 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in three equal annual installments beginning on October 14, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in three equal annual installments beginning on October 14, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.